Kymera Therapeutics, Inc. Common Stock (KYMR) is a publicly traded Healthcare sector company. As of August 27, 2026, KYMR trades at $122.10 with a market cap of $10.53B and a P/E ratio of -38.32. KYMR moved -2.75% today. Year to date, KYMR is +72.55%; over the trailing twelve months it is +186.19%. Its 52-week range spans $19.45 to $130.05. Analyst consensus is strong buy with an average price target of $131.33. Rallies surfaces KYMR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks KYMR insider trades, Form 4 activity, executive purchases, executive sales, shares, prices, and transaction dates when available.
| Metric | Value |
|---|---|
| Price | $122.10 |
| Market Cap | $10.53B |
| P/E Ratio | -38.32 |
| EPS | $-3.25 |
| Dividend Yield | 0.00% |
| 52-Week High | $130.05 |
| 52-Week Low | $19.45 |
| Volume | 10 |
| Avg Volume | 0 |
| Revenue (TTM) | $105.00M |
| Net Income | $-299.60M |
| Gross Margin | 0.00% |
18 analysts cover KYMR: 0 strong buy, 16 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $131.33.